Theory Paper IDrNB Cardiology – Theory Notes

NOVEL APPROACHES IN PREVENTIVE CARDIOLOGY

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

ITHE CARDIOVASCULAR-KIDNEY-METABOLIC (CKM) PARADIGM AND PREVENT EQUATIONS

  • The AHA CKM Syndrome Framework (Ndumele et al., Circulation 2023): Contemporary preventive cardiology has shifted from managing isolated risk factors in silos to staging and treating the interconnected Cardiovascular-Kidney-Metabolic (CKM) Syndrome across Stages 0 to 4 (Stage 0: no risk factors; Stage 1: excess/dysfunctional visceral adiposity; Stage 2: metabolic risk factors [T2DM, HTN, hypertriglyceridemia] or moderate-to-high-risk CKD; Stage 3: subclinical ASCVD/HF [CAC >0 or elevated NT-proBNP/troponin]; Stage 4: clinical CVD).
  • The AHA PREVENT Risk Equations (2023/2024): Replaces the 2013 Pooled Cohort Equations (PCE) by removing race, starting risk estimation at age 30 years (estimating both 10-year and 30-year risk of total CVD, ASCVD, and Heart Failure), and integrating eGFR and urine albumin-to-creatinine ratio (uACR) alongside HbA1c and social deprivation indices.
  • Incretin-Based Cardioprotection (GLP-1 and Dual GIP/GLP-1 Receptor Agonists):
    • SELECT Trial (NEJM 2023 — Semaglutide): In 17,604 patients with established CVD and overweight/obesity (BMI 27 kg/m2 or greater) without diabetes, subcutaneous Semaglutide (2.4 mg weekly) reduced 3-point MACE (CV death, non-fatal MI, or non-fatal stroke) by 20 percent (HR 0.80), establishing GLP-1 receptor agonists as foundational cardiovascular secondary-prevention agents independent of glycemia.
    • STEP-HFpEF (2023), FLOW (2024), and SUMMIT (2024 — Tirzepatide) Trials: Semaglutide improved symptoms/6MWD in obese HFpEF (STEP-HFpEF) and reduced major kidney disease progression and CV death by 24 percent in diabetic CKD (FLOW), while the dual GIP/GLP-1 agonist Tirzepatide reduced the composite of CV death or worsening heart failure events by 38 percent in obese HFpEF (SUMMIT Trial, NEJM 2024).
    • SGLT2 Inhibitors and Non-Steroidal MRAs (Finerenone): Empagliflozin and Dapagliflozin (EMPA-KIDNEY, DAPA-CKD) and the selective non-steroidal MRA Finerenone (FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF in HFmrEF/HFpEF, NEJM 2024) halt cardiorenal progression and prevent heart failure hospitalizations across the CKM spectrum.

IIADVANCED LIPID, GENETIC SILENCING AND ANTI-INFLAMMATORY THERAPIES

  • Small Interfering RNA (siRNA) Against PCSK9 (Inclisiran): Conjugated with Triantennary N-Acetylgalactosamine (GalNAc) for selective hepatocyte uptake via asialoglycoprotein receptors, Inclisiran degrades PCSK9 mRNA via the RISC complex. Dosed subcutaneously on Day 1, Month 3, and every 6 months thereafter, it provides sustained ~50 percent LDL-C reduction (ORION-9, -10, -11 trials; Phase III VICTORION-2 PREVENT and ORION-4 MACE outcome trials ongoing).
  • ATP Citrate Lyase Inhibition (Bempedoic Acid — CLEAR Outcomes Trial, NEJM 2023): Oral prodrug activated exclusively in the liver by ACSVL1 (absent in skeletal muscle, avoiding myalgia) that inhibits cholesterol synthesis upstream of HMG-CoA reductase; reduced 4-point MACE by 13 percent (and MI by 23 percent) in statin-intolerant patients.
  • Targeting Lipoprotein(a) [Lp(a)]:
    • Antisense Oligonucleotide (Pelacarsen) vs. Next-Generation siRNAs (Olpasiran, Zerlasiran, Lepodisiran) and Oral Muvalaplin: While the Phase III Lp(a)HORIZON Trial of Pelacarsen (80% Lp(a) reduction) announced in September 2026 that it did not reach statistical significance for its primary 4-point MACE endpoint, deeper Lp(a) suppression (95 to 99 percent reduction) with quarterly/biannual siRNAs is being tested in ongoing Phase III outcome trials (OCEAN(a)-Outcomes with Olpasiran and ACCLAIM-Lp(a) with Lepodisiran), alongside the oral small-molecule Lp(a) assembly inhibitor Muvalaplin (KRAKEN Trial).
    • RNAi for Resistant Hypertension and Hypertriglyceridemia: Biannual subcutaneous Zilebesiran (siRNA silencing hepatic angiotensinogen; KARDIA-1, KARDIA-2, KARDIA-3) and Olezarsen / Plozasiran (targeting APOC3) or Zodasiran (targeting ANGPTL3).
    • Residual Inflammatory Risk Targeting: Low-dose Colchicine (0.5 mg daily) (COLCOT and LoDoCo2 trials; Class IIa in the 2024 ESC Chronic Coronary Syndromes Guidelines) targets the NLRP3 inflammasome / IL-1beta / IL-6 pathway in patients with chronic atherosclerotic disease.
Novel Preventive Pillar Target & Mechanism Key Clinical Trial / Evidence Primary Preventive Impact
Semaglutide / Tirzepatide GLP-1 RA / Dual GIP-GLP-1 RA SELECT (2023), FLOW (2024), SUMMIT (2024) 20% MACE reduction in non-DM obesity (SELECT); 38% CV death/HF reduction in obese HFpEF (SUMMIT)
Bempedoic Acid Hepatic ATP Citrate Lyase (ACL) inhibitor (ACSVL1 prodrug) CLEAR Outcomes (NEJM 2023) 13% 4-point MACE reduction (23% MI reduction) in statin-intolerant primary/secondary prevention
Inclisiran GalNAc-conjugated PCSK9 siRNA ORION-9/10/11; VICTORION-2 PREVENT (ongoing) ~50% sustained LDL-C reduction with biannual dosing, overcoming daily pill non-adherence
Lp(a) RNA Therapeutics LPA mRNA ASO (Pelacarsen) & siRNAs (Olpasiran, Lepodisiran) Lp(a)HORIZON (neutral MACE, Sept 2026); OCEAN(a)-Outcomes (ongoing) 80–98% Lp(a) reduction; testing whether ultra-deep siRNA suppression reduces MACE
Low-Dose Colchicine (0.5 mg) Tubulin / NLRP3 inflammasome inhibitor COLCOT (2019), LoDoCo2 (2020) 23–31% MACE reduction in chronic CAD (Class IIa in 2024 ESC CCS Guidelines)

IIIPRECISION IMAGING AND GENOMIC PLAQUE CHARACTERIZATION

  • Coronary Artery Calcium (CAC) and AI-Enabled Quantitative Coronary CTA (AI-QCT): Moves risk stratification from population probability equations to direct visualization of individual atherosclerotic plaque burden:
  • High-Risk Vulnerable Plaque Features on CCTA: Identifies Low-Attenuation Plaque (necrotic lipid core <30 Hounsfield Units), Positive Vessel Remodeling (remodeling index >=1.1), Spotty Calcification, and the Napkin-Ring Sign (high-risk plaque features, particularly low-attenuation plaque, predicted future MI independent of stenosis severity in the SCOT-HEART and PROMISE trials).
  • Perivascular Fat Attenuation Index (FAI): CT measurement of perivascular adipose tissue inflammation around the proximal coronary arteries (CRISP-CT / ORFAN studies), identifying inflamed coronary arteries prior to plaque rupture.
  • Polygenic Risk Scores (PRS): Aggregates the weighted effect of millions of common SNPs to identify young individuals in the top 8 percent of genetic risk (who carry a 3-fold or greater CAD risk, equivalent to monogenic Familial Hypercholesterolemia) decades before clinical events occur.

IVDIGITAL HEALTH AND WEARABLE DIAGNOSTICS

  • Validated Out-of-Office BP and Wearable PPG/ECG: While cuff-based HBPM and 24-hour ABPM remain the 2024 ESC Guideline Class I standard (as cuffless photoplethysmography [PPG] smartwatch blood pressure devices are not yet recommended for clinical decision-making due to calibration drift), smartwatch PPG with single-lead ECG confirmation is validated for opportunistic Atrial Fibrillation detection (Apple Heart Study, Huawei Heart Study) and is being tested for rhythm-guided anticoagulation (REACT-AF Trial).

VPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT (CSI / LAI CONSENSUS)

  • Addressing Early-Onset Malignant CAD in South Asians: Because Indians develop first myocardial infarction 8 to 10 years earlier than Western populations with high rates of visceral adiposity (“thin-fat” phenotype), insulin resistance, and elevated Lipoprotein(a), the Lipid Association of India (LAI) and CSI recommend starting formal ASCVD risk screening by age 20 to 30 years, measuring Lp(a) at least once in every adult, and targeting LDL-C less than 50 to 55 mg/dL in very-high-risk and less than 30 to 40 mg/dL in extreme-risk secondary prevention patients.

Key references

  • Ndumele CE, Rangaswami J, Chow SL, et al.: Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association, Circulation, 2023.
  • Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (SELECT Trial Investigators): Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, New England Journal of Medicine, 2023.
  • Nissen SE, Lincoff AM, Brennan D, et al. (CLEAR Outcomes Investigators): Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients, New England Journal of Medicine, 2023.
  • Vrints C, Andreotti F, Koskinas KC, et al.: 2024 ESC Guidelines for the management of chronic coronary syndromes, European Heart Journal, 2024.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.